We are excited to officially announce our participation in the 2025 ATS International Conference, which will be held from May 18 to 21, 2025! It is our privilege to connect with clinicians, researchers, and all the participants from around the world, share our latest research, and exchange valuable insights. We anticipate engaging discussions, fostering collaborations, and promoting innovations in science and medicine—looking forward to seeing you there!
What is ATS International Conference
The ATS International Conference is a leading global event dedicated to pulmonary, critical care, and sleep medicine. It brings together clinicians, researchers, and laboratories worldwide. ATS 2025 in San Francisco will feature the latest advancements in clinical, basic, and translational science, presented through a variety of formats, including scientific sessions, workshops, and educational programs.
Event Overview
Date: May 18-21, 2025
Venue: Moscone Center, 747 Howard Street, San Francisco, CA
Event Schedule
The ATS 2025 Conference will feature Pre-Conference Education Programs and Events on May 16–17, followed by the International Conference from May 18-21. Participants will have opportunities to network, collaborate, and engage with professionals throughout the event. For more details on the conference schedule, please refer to ATS 2025.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the ATS 2025 in San Francisco, CA!
